Pulmonx Stock Rises On Narrowed Q2 Losses, Margin Gains
Pulmonx (LUNG) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue fell 5% to $22.8M, while gross profit rose to $17.7M and gross margin increased to 78%. Net loss narrowed to $10.1M ($0.24/share). The company reaffirmed FY2026 revenue guidance of $90M-$92M and gross margin around 76%.
How this was made
The 30-second read
Why it matters
The key tradable elements are the narrowed loss, higher gross margin, and reaffirmed full-year revenue and gross margin guidance, which together can shift expectations for profitability trajectory.
Market read
Investors are likely reacting to profitability improvement and guidance reaffirmation, even as revenue continues to decline and China regulatory delays remain a risk.
What to watch
China-related regulatory delays are cited as a drag; traders may need confirmation that those delays are not worsening, and that gross margin can sustain near 76% into FY2026.
Background
Pulmonx is a medical device company focused on minimally invasive treatments for lung disease; this article summarizes its Q2 2026 financials and FY2026 outlook.
Ticker impact
Pulmonx reported Q2 revenue of $22.8M (down 5% YoY) but narrowed net loss to $10.1M and reaffirmed FY2026 revenue guidance of $90M-$92M.
Bias modestly positive for the next few sessions as traders price in improved profitability while monitoring whether China-related delays ease.
The article provides concrete quarterly profitability improvement (gross margin 78% vs 72%, net loss narrowing) and explicit FY guidance ranges, which typically drive follow-through versus purely narrative coverage.
Market effects
Signals continued cost realignment and margin discipline in minimally invasive lung disease devices, which can modestly support the group’s risk appetite.
No direct regional macro catalyst beyond mention of China regulatory delays affecting international growth.
Limited spillover; the update is company-specific with no stated industry-wide regulatory or reimbursement change.
Counterpoint
The top-line is still declining (revenue down 5% YoY), so the rally may be over-discounting temporary margin gains versus longer-term demand and regulatory headwinds.
Key entities
- companyPulmonx Corporation
Reported Q2 2026 results with improved margins and narrowed net loss, and reaffirmed FY2026 guidance.